Ignite Creation Date:
2024-05-06 @ 10:18 AM
Last Modification Date:
2024-10-26 @ 12:27 PM
Study NCT ID:
NCT03214250
Status:
COMPLETED
Last Update Posted:
2022-12-23
First Post:
2017-06-09
Brief Title:
Safety and Efficacy of APX005M With Gemcitabine and Nab-Paclitaxel With or Without Nivolumab in Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma
Sponsor:
Parker Institute for Cancer Immunotherapy
Organization:
Parker Institute for Cancer Immunotherapy
Organization Data
Organization:
Parker Institute for Cancer Immunotherapy
Class:
OTHER
Study ID:
PICI0002
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Parker Institute for Cancer Immunotherapy
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Bristol-Myers Squibb | INDUSTRY |
| Apexigen America Inc | INDUSTRY |
| Cancer Research Institute New York City | OTHER |